In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis

Mycopathologia

Volumn 173, Issue 1, 2012, Pages 35-46

  Marcos Arias, Cristina ^a   Eraso, Elena ^a   Madariaga, Lucila ^a   Carrillo Muñoz, Alfonso Javier ^b   Quindós, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Associacio Catalana d'Intelligencia Artificial   (Spain)

Author keywords

Antifungal; Candida; Denture stomatitis; Posaconazole; Susceptibility; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; POSACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; CANDIDA; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STOMATITIS;

ANTIFUNGAL AGENTS; CANDIDA; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; STOMATITIS, DENTURE; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; SACCHAROMYCES CEREVISIAE;

EID: 82455212909     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-011-9460-4     Document Type: Article

References (59)

1. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW. Candida-associated denture stomatitis. Aetiology and management: a review. Part 3. Treatment of oral candidosis. Aust Dent J. 1998; 43: 244-9.
2. Barbeau J, Seguin J, Goulet JP, de Louis K, Avon Sl, Lalonde B, et al. Reassessing the presence of Candida albicans in denture-related stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95: 51-9.
3. Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 98: 53-9.
4. Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. J Dent Res. 2007; 86: 204-15.
5. Marcos-Arias C, Vicente JL, Sahand IH, Eguía A, De-Juan A, Madariaga L, et al. Isolation of Candida dubliniensis in denture stomatitis. Arch Oral Biol. 2009; 54: 127-31.
6. Samaranayake LP, Keung LW, Jin L. Oral mucosal fungal infections. Periodontology. 2009; 49: 39-59.
7. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002; 359: 1135-44.
8. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009; 53: 5026-34.
9. Quindós G, Carrillo-Muñoz AJ, Eraso E, Cantón E, Pemán J. In vitro antifungal activity of voriconazole: new data after the first year of clinical experience. Rev Iberoam Micol. 2007; 24: 198-208.
10. Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses. 2010; 53: 434-7.
11. Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology. 2010; 98: 15-25.
12. Bissell V, Felix DH, Wray D. Comparative trial of fluconazole and amphotericin in the treatment of denture stomatitis. Oral Surg Oral Med Oral Pathol. 1993; 76: 35-9.
13. Martín-Mazuelos E, Aller AI, Romero MJ, Rodríguez AA, Gutiérrez MJ, Bernal S, et al. Response to fluconazole and itraconazole of Candida spp. in denture stomatitis. Mycoses. 1997; 40: 283-9.
14. Quindós G, Sánchez Vargas LO, Villar-Vidal M, Eraso E, Alkorta M, Hernández-Almaraz JL. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents. 2008; 31: 266-71.
15. Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanism, epidemiology, and clinical significance. J Invasive Fungal Infect. 2007; 1: 74-92.
16. Bergendal T, Holmberg K, Nord CE. Yeast colonization in the oral cavity and feces in patients with denture stomatitis. Acta Odontol Scand. 1979; 37: 37-45.
17. Cross LJ, Bagg J, Aitchison TC. Efficacy of the cyclodextrin liquid preparation of itraconazole in treatment of denture stomatitis: comparison with itraconazole capsules. Antimicrob Agents Chemother. 2000; 44: 425-7.
18. Cross LJ, Williams DW, Sweeney CP, Jackson MS, Lewis MA, Bagg J. Evaluation of the recurrence of denture stomatitis and Candida colonization in a small group of patients who received itraconazole. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97: 351-8.
19. Eraso E, Moragues MD, Villar-Vidal M, Sahand IH, González-Gómez N, Pontón J, et al. Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species. J Clin Microbiol. 2006; 44: 3340-5.
20. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Wayne: CLSI; 2008.
21. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; informational supplement, 3rd ed. CLSI document M27-S3. Wayne: CLSI; 2008.
22. Cross LJ, Riggio MP, Bagg J. Genetic typing of Candida albicans strains isolated from the oral cavity of patients with denture stomatitis before and after itraconazole therapy. Microbial Ecol Health Dis. 1999; 11: 35-40.
23. Budtz-Jorgensen E, Holmstrup P, Krogh P. Fluconazole in the treatment of Candida-associated denture stomatitis. Antimicrob Agents Chemother. 1988; 32: 1859-63.
24. Pereira-Cenci T, Del Bel Cury AA, Crielaard W, ten Cate JM. Development of Candida-associated denture stomatitis: new insights. J Appl Oral Sci. 2008; 16: 86-94.
25. Zomorodian K, Haghighi NN, Rajaee N, Pakshir K, Tarazooie B, Vojdani M, et al. Assessment of Candida species colonization and denture-related stomatitis in complete denture wearers. Med Mycol. 2011; 49: 208-11.
26. Knechtel SA, Klepser ME. Amphotericin B resistance: epidemiology, mechanism, and clinical relevance. J Invasive Fungal Infect. 2007; 1: 93-8.
27. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002; 49(Suppl 1): 7-10.
28. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis. 2003; 36: S31-41.
29. Pfaller MA, Messer SA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis. 1998; 32: 223-7.
30. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004; 42: 4419-31.
31. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988; 84: 826-32.
32. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990; 28: 1616-22.
33. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, et al. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol. 2002; 40: 1406-12.
34. Carrillo-Muñoz AJ, Quindós G, Tur C, Ruesga MT, Miranda Y, del Valle O, et al. In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother. 1999; 44: 397-401.
35. Quindós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, et al. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis. 2000; 19: 645-8.
36. das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, et al. Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs. 2008; 68: 1787-802.
37. Carrillo-Muñoz AJ, Tur-Tur C, Hernández-Molina JM, Santos P, Cárdenes D, Giusiano G. Antifungal agents for onychomycoses. Rev Iberoam Micol. 2010; 27: 49-56.
38. Hapala I, Klobucnikova V, Mazanova K, Kohut P. Two mutants selectively resistant to polyenes reveal distinct mechanisms of antifungal activity by nystatin and amphotericin B. Biochem Soc Trans. 2005; 33: 1206-9.
39. Kobayashi D, Kondo K, Uehara N, Otokozawa S, Tsuji N, Yagihashi A, et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob Agents Chemother. 2002; 46: 3113-7.
40. Thevissen K, Ayscough KR, Aerts AM, Du W, De BK, Meert EM, et al. Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast. J Biol Chem. 2007; 282: 21592-7.
41. Vandenbosch D, Braeckmans K, Nelis HJ, Coenye T. Fungicidal activity of miconazole against Candida spp. biofilms. J Antimicrob Chemother. 2010; 65: 694-700.
42. Bensadoun RJ, Daoud J, El GB, Bastit L, Gourmet R, Rosikon A, et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008; 112: 204-11.
43. van RJ, Haxaire M, Kamya M, Lwanga I, Katabira E. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr. 2004; 35: 144-50.
44. Bagg J, Sweeney MP, Davies AN, Jackson MS, Brailsford S. Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer. J Med Microbiol. 2005; 54: 959-64.
45. Pelletier R, Loranger L, Marcotte H, De CE. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol. 2002; 51: 479-83.
46. Phillips P, De BK, Frechette G, Tchamouroff S, Vandercam B, Weitner L, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis. 1998; 26: 1368-73.
47. Sánchez Vargas LO, Eraso E, Carrillo-Muñoz AJ, Aguirre JM, Gaitán-Cepeda LA, Quindós G. In vitro activity of voriconazole against Mexican oral yeast isolates. Mycoses. 2010; 53: 200-3.
48. Koks CH, Meenhorst PL, Bult A, Beijnen JH. Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res. 2002; 46: 195-201.
49. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother. 2005; 56(Suppl 1): i33-8.
50. Chen A, Sobel JD. Emerging azole antifungals. Expert Opin Emerg Drugs. 2005; 10: 21-33.
51. Arias A, Arévalo MP, Andreu A, Rodríguez C, Sierra A. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents. Mycoses. 1994; 37: 285-9.
52. Carrillo-Muñoz AJ, Quindós G, Ruesga M, Alonso R, del Valle O, Hernández-Molina JM, et al. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother. 2005; 55: 317-9.
53. Carrillo-Muñoz AJ, Tur-Tur C, Hernández-Molina JM, Quindós G, Marcos-Arias C, Eraso E, et al. Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates. Rev Esp Quimioter. 2010; 23: 122-5.
54. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2, 000 blood stream Candida isolates in the United States. Antimicrob Agents Chemother. 2003; 47: 3149-54.
55. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and national committee for clinical laboratory standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother. 1995; 39: 2520-2.
56. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004; 53: 74-80.
57. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13, 338 clinical isolates of Candida spp. tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol. 2007; 45: 70-5.
58. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol. 2008; 46: 551-9.
59. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50: 2009-15.